ADHD PreSMA Response Inhibition Therapy

Description

ADHD children have abnormal inhibitory control, meaning they have trouble stopping themselves from doing something they should not do. This ability to control involves an area in the brain called the pre-supplementary motor area (pre-SMA). Scientists have previously shown that the pre-SMA is abnormal in ADHD patients. In this study, we will use Transcranial Magnetic Stimulation (TMS) to stimulate the pre-SMA and determine the effects on measures that are related to inhibitory control.

Conditions

Attention Deficit Hyperactivity Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

ADHD children have abnormal inhibitory control, meaning they have trouble stopping themselves from doing something they should not do. This ability to control involves an area in the brain called the pre-supplementary motor area (pre-SMA). Scientists have previously shown that the pre-SMA is abnormal in ADHD patients. In this study, we will use Transcranial Magnetic Stimulation (TMS) to stimulate the pre-SMA and determine the effects on measures that are related to inhibitory control.

ADHD PreSMA Response Inhibition Therapy

ADHD PreSMA Response Inhibition Therapy

Condition
Attention Deficit Hyperactivity Disorder
Intervention / Treatment

-

Contacts and Locations

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. ADHD diagnosis
  • 2. Ages 12-17 years
  • 3. Stimulant use is allowed but must be discontinued 24 hours prior to and during days of TMS visit
  • 1. Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, epilepsy or seizure disorders, traumatic brain injury, brain tumor, stroke, intellectual disability, cerebral palsy, neurodegenerative conditions, hearing impairment, metallic objects in the head or any other serious medical condition
  • 2. Presence of any implanted medical devices (e.g., ports, shunts, stimulators, cochlear implants)
  • 3. For biological females who are post-menarche, current pregnancy based on urine pregnancy test.
  • 4. Baseline problem of hearing impairment or chronic tinnitus
  • 5. Any clinically significant finding on brain MRI
  • 6. History of DSM-5 conduct disorder, major depressive disorder, bipolar disorder, obsessive compulsive disorder, anxiety disorder, psychotic disorder
  • 7. Non-stimulant medication(s) for ADHD (e.g., alpha2 adrenergic agonist, atomoxetine, tricyclics)
  • 8. Neuroleptic/antipsychotic medication(s)
  • 9. Inability to undergo MRI
  • 10. Active suicidality, history of suicidality, or high risk for suicide as assessed by a study physician
  • 11. Substance abuse or dependence within the past year, based on 1) separate screening process of asking parent/guardian and participant, and 2) positive urine drug screen. Exception will be made for positive urine drug screen due to prescribed ADHD medication

Ages Eligible for Study

12 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital Medical Center, Cincinnati,

Steve W Wu, M.D., PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati

Study Record Dates

2026-12-31